

Seung-Cheol Shim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3927470/publications.pdf>

Version: 2024-02-01

90
papers

3,214
citations

185998

28
h-index

168136

53
g-index

92
all docs

92
docs citations

92
times ranked

5531
citing authors

#	ARTICLE	IF	CITATIONS
1	STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis. <i>Rheumatology</i> , 2021, 60, 3923-3935.	0.9	24
2	Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 632-640.	0.5	103
3	Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence. <i>Journal of Korean Medical Science</i> , 2021, 36, e208.	1.1	8
4	Clonorchis sinensis-Derived Protein Attenuates Inflammation and New Bone Formation in Ankylosing Spondylitis. <i>Frontiers in Immunology</i> , 2021, 12, 615369.	2.2	6
5	A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1125-1132.	1.5	1
6	Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1438-1445.	0.5	26
7	Self-care recommendations for patients with rheumatic diseases during the COVID-19 pandemic. <i>Rheumatology International</i> , 2020, 40, 1347-1349.	1.5	9
8	Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies. <i>Journal of Korean Medical Science</i> , 2020, 35, e335.	1.1	4
9	Positive histopathologic assessment in salivary glands shows little impact on clinical features of established primary Sjögren's syndrome in a Korean population. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 158-165.	0.4	0
10	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	2.9	64
11	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. <i>Rheumatology</i> , 2019, 58, 2193-2202.	0.9	34
12	Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. <i>Arthritis Research and Therapy</i> , 2019, 21, 122.	1.6	12
13	Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. <i>PLoS Genetics</i> , 2019, 15, e1008092.	1.5	36
14	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial. <i>BioDrugs</i> , 2019, 33, 79-91.	2.2	26
15	254 Identification of damage clusters in systemic lupus erythematosus. , 2019, , .		0
16	Anti-TIF1 ^β antibody and the expression of TIF1 ^β in idiopathic inflammatory myopathies. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 314-320.	0.9	7
17	High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis. <i>Patient</i> , 2019, 12, 319-326.	1.1	1
18	Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 917-931.	0.7	20

#	ARTICLE	IF	CITATIONS
19	Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren's syndrome: data from a nationwide cohort for Sjögren's syndrome in Korea. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 107-113.	0.4	6
20	Intrinsic changes of left ventricular function in patients with Behçet disease and comparison according to systemic disease activity. <i>Echocardiography</i> , 2018, 35, 809-816.	0.3	6
21	Serum and synovial fluid concentrations of cold-inducible κ RNA-binding protein in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 148-154.	0.9	25
22	Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1001-1009.	0.9	5
23	Prevalence of comorbidities and evaluation of their monitoring in Korean patients with rheumatoid arthritis: comparison with the results of an international, cross-sectional study (κ COMORA). <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1414-1422.	0.9	12
24	Productivity Loss of Rheumatoid Arthritis Patients according to the Their Stages of the Disease Activity Score. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 122.	0.4	2
25	Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis. <i>Archives of Rheumatology</i> , 2018, 33, 389-394.	0.3	17
26	Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea. <i>Journal of Korean Medical Science</i> , 2018, 33, e346.	1.1	5
27	Wolves Trapped in the NETs—The Pathogenesis of Lupus Nephritis. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 81.	0.4	3
28	Performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome in a Korean cohort. <i>Rheumatology International</i> , 2018, 38, 1651-1660.	1.5	10
29	Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. <i>MAbs</i> , 2018, 10, 934-943.	2.6	43
30	Prevalence and Associated Factors for Non-adherence in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 47.	0.4	9
31	Switching to biosimilars in the treatment of rheumatic diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 557-571.	1.3	6
32	N-3 polyunsaturated fatty acids restore Th17 and Treg balance in collagen antibody-induced arthritis. <i>PLoS ONE</i> , 2018, 13, e0194331.	1.1	56
33	Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 1224-1233.	0.7	5
34	A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 65-71.	0.5	39
35	A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 566-570.	0.5	78
36	Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial. <i>BioDrugs</i> , 2017, 31, 357-367.	2.2	28

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. <i>BioDrugs</i> , 2017, 31, 369-377.	2.2	41
38	Expression of activation-induced cytidine deaminase splicing variants in patients with ankylosing spondylitis. <i>Autoimmunity</i> , 2017, 50, 435-440.	1.2	1
39	Impact of early diagnosis on functional disability in rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 738-746.	0.7	15
40	Long-term Treatment with Anti-platelet Agents for Collagen-induced Arthritis Improves Radiological Findings. <i>Osong Public Health and Research Perspectives</i> , 2017, 8, 179-184.	0.7	0
41	Identification of a Systemic Lupus Erythematosus Risk Locus Spanning <i>ATG16L2</i> , <i>FCHSD2</i> , and <i>P2RY2</i> in Koreans. <i>Arthritis and Rheumatology</i> , 2016, 68, 1197-1209.	2.9	89
42	Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study. <i>Journal of Cardiovascular Imaging</i> , 2016, 24, 312.	0.8	9
43	Association of Single Nucleotide Polymorphisms of <i>PADI4</i> and <i>HLA-DRB1</i> Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases. <i>Lung</i> , 2016, 194, 745-753.	1.4	17
44	Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. <i>Rheumatology International</i> , 2016, 36, 505-513.	1.5	18
45	Developing a Risk-scoring Model for Ankylosing Spondylitis Based on a Combination of <i>HLA-B27</i> , Single-nucleotide Polymorphism, and Copy Number Variant Markers. <i>Journal of Rheumatology</i> , 2016, 43, 2136-2141.	1.0	7
46	Association-heterogeneity mapping identifies an Asian-specific association of the <i>GTF2I</i> locus with rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 27563.	1.6	23
47	High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. <i>Nature Genetics</i> , 2016, 48, 323-330.	9.4	219
48	Visual Assessment of Chest Computed Tomography Findings in Anti-cyclic Citrullinated Peptide Antibody Positive Rheumatoid Arthritis: Is it Associated with Airway Abnormalities?. <i>Lung</i> , 2016, 194, 97-105.	1.4	11
49	Imputing Variants in <i>HLA-DR Beta</i> Genes Reveals That <i>HLA-DRB1</i> Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2016, 11, e0150283.	1.1	20
50	Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. <i>PLoS ONE</i> , 2016, 11, e0153816.	1.1	15
51	An <i>HLA-C</i> amino-acid variant in addition to <i>HLA-B*27</i> confers risk for ankylosing spondylitis in the Korean population. <i>Arthritis Research and Therapy</i> , 2015, 17, 342.	1.6	21
52	Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients. <i>Journal of Immunology Research</i> , 2015, 2015, 1-7.	0.9	11
53	High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e13-e13.	0.5	100
54	<i>ERAP2</i> is associated with ankylosing spondylitis in <i>HLA-B27</i> -positive and <i>HLA-B27</i> -negative patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1627-1629.	0.5	86

#	ARTICLE	IF	CITATIONS
55	Heterozygote genotypes for PADI4_89 were protectively associated with susceptibility to tuberculosis in Koreans. <i>Rheumatology International</i> , 2015, 35, 651-655.	1.5	6
56	Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor- α treatment and comparison to other guidelines. <i>Rheumatology International</i> , 2015, 35, 1817-1823.	1.5	6
57	Factors Associated with the Use of Complementary and Alternative Medicine for Korean Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2075-2081.	1.0	19
58	Leukocyte-specific protein 1 regulates T-cell migration in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6535-43.	3.3	28
59	Prediction for TNF Inhibitor Users in RA Patients According to Reimbursement Criteria Based on DAS28. <i>Journal of Rheumatic Diseases</i> , 2014, 21, 64.	0.4	6
60	Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial. <i>Current Medical Research and Opinion</i> , 2014, 30, 2399-2408.	0.9	11
61	Restoration of Overexpressed Variable Heavy Chain 2 Transcripts with Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2014, 41, 613-614.	1.0	1
62	Genome-Wide Copy Number Variation Analysis Identifies Deletion Variants Associated With Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2103-2112.	2.9	29
63	Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. <i>Human Molecular Genetics</i> , 2014, 23, 1656-1668.	1.4	67
64	Efficacy and safety of PG201 (Layla [®]) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study. <i>Rheumatology International</i> , 2014, 34, 1369-1378.	1.5	17
65	Ethnic specificity of lupus-associated loci identified in a genome-wide association study in Korean women. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1240-1245.	0.5	61
66	Bone Morphogenetic Protein 6 Polymorphisms Are Associated with Radiographic Progression in Ankylosing Spondylitis. <i>PLoS ONE</i> , 2014, 9, e104966.	1.1	24
67	Effect of n-3 polyunsaturated fatty acid supplementation in patients with rheumatoid arthritis: a 16-week randomized, double-blind, placebo-controlled, parallel-design multicenter study in Korea. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1367-1372.	1.9	45
68	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , 2013, 45, 730-738.	9.4	699
69	Diagnosis and Treatment of Lupus Nephritis: Survey Results on Four Important Issues. <i>Journal of Rheumatic Diseases</i> , 2013, 20, 156.	0.4	1
70	Long-term Safety and Efficacy of Abatacept in Koreans with Rheumatoid Arthritis. <i>Journal of Rheumatic Diseases</i> , 2013, 20, 30.	0.4	1
71	Variation in the <i>ICAM1-ICAM4-ICAM5</i> locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1809-1814.	0.5	60
72	Korean Observational Study Network for Arthritis (KORONA): Establishment of a Prospective Multicenter Cohort for Rheumatoid Arthritis in South Korea. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 745-751.	1.6	54

#	ARTICLE	IF	CITATIONS
73	The potential role of VPREB1 gene copy number variation in susceptibility to rheumatoid arthritis. <i>Molecular Immunology</i> , 2011, 48, 1338-1343.	1.0	24
74	Genome-wide association study of rheumatoid arthritis in Koreans: Population-specific loci as well as overlap with European susceptibility loci. <i>Arthritis and Rheumatism</i> , 2011, 63, 884-893.	6.7	121
75	Genetic Studies of Ankylosing Spondylitis in Koreans Confirm Associations with <i>ERAP1</i> and 2p15 Reported in White Patients. <i>Journal of Rheumatology</i> , 2011, 38, 322-324.	1.0	36
76	Common variants at the promoter region of the <i>APOM</i> confer a risk of rheumatoid arthritis. <i>Experimental and Molecular Medicine</i> , 2011, 43, 613.	3.2	31
77	Replicated association of a regulatory polymorphism in the interferon β gene with lupus susceptibility: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1878-1879.	0.5	4
78	Associations of Vitamin D Binding Protein Gene Polymorphisms with the Development of Peripheral Arthritis and Uveitis in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 2224-2229.	1.0	32
79	Anti-cyclic citrulline peptide antibody in non-tuberculous mycobacteria sera: a negative association. <i>Clinical Rheumatology</i> , 2010, 29, 335-336.	1.0	5
80	<i>ARTS1</i> polymorphisms are associated with ankylosing spondylitis in Koreans. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 582-584.	0.5	54
81	Anti-Cyclic Citrullinated Peptide Antibodies Distinguish Hepatitis B Virus (HBV)-associated Arthropathy from Concomitant Rheumatoid Arthritis in Patients with Chronic HBV Infection. <i>Journal of Rheumatology</i> , 2009, 36, 712-716.	1.0	19
82	Polymorphisms of <i>COTL1</i> gene identified by proteomic approach and their association with autoimmune disorders. <i>Experimental and Molecular Medicine</i> , 2009, 41, 354.	3.2	26
83	Association of <i>TBX21</i> polymorphisms in a Korean population with rheumatoid arthritis. <i>Experimental and Molecular Medicine</i> , 2009, 41, 33.	3.2	29
84	Association of <i>FOXJ1</i> polymorphisms with systemic lupus erythematosus and rheumatoid arthritis in Korean population. <i>Experimental and Molecular Medicine</i> , 2007, 39, 805-811.	3.2	21
85	A 2-Week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain. <i>Clinical Therapeutics</i> , 2007, 29, 1381-1389.	1.1	23
86	Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: A 1-Week, randomized, double-blind, placebo-controlled trial. <i>Clinical Therapeutics</i> , 2006, 28, 2052-2060.	1.1	36
87	The polymorphisms of <i>Tim-1</i> promoter region are associated with rheumatoid arthritis in a Korean population. <i>Immunogenetics</i> , 2005, 56, 696-701.	1.2	50
88	<i>Eotaxin-3</i> gene polymorphisms are associated with rheumatoid arthritis in a Korean population. <i>Human Immunology</i> , 2005, 66, 314-320.	1.2	19
89	The polymorphisms of <i>Th1</i> cell surface gene <i>Tim-3</i> are associated in a Korean population with rheumatoid arthritis. <i>Immunology Letters</i> , 2004, 95, 91-95.	1.1	72
90	The exon 4 variations of <i>Tim-1</i> gene are associated with rheumatoid arthritis in a Korean population. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 971-975.	1.0	38